Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14886565 | 0.95 | KDM4E (0.51) | PTGS2PTGS1ALOX5KDM4EALDH1A1 | |
| SCHEMBL10059772 | 0.84 | SCD (0.43) | PTGS2PTGS1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL10059921 | 0.84 | KDM4E (0.46) | PTGS2PTGS1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL10021078 | 0.82 | ALDH1A1 (0.60) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL10079417 | 0.80 | CA2 (0.58) | PTGS2PTGS1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL10079720 | 0.79 | ALDH1A1 (0.47) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL1687503 | 0.78 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL8770202 | 0.78 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL10078777 | 0.78 | IDH1 (0.53) | PTGS1KDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL10059769 | 0.78 | CYP1A2 (0.52) | PTGS2KDM4EALDH1A1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2296653-B1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | UNIVERSITY OF MINNESOTA (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110218515-A1 | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | TNNI3, FABP3, TNNT2 | PTGS2 34/4885PTGS1 16/4885ALOX5 169/4885 |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | PTGS2 117/4885PTGS1 76/4885ALOX5 825/4885 |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | PTGS2 117/4885PTGS1 76/4885ALOX5 825/4885 |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | MMP1, MMP8, CCL11 | PTGS2 292/4885PTGS1 185/4885ALOX5 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.